{"id":2784,"date":"2025-07-16T23:00:00","date_gmt":"2025-07-16T14:00:00","guid":{"rendered":"https:\/\/allaboutenglishmastery.com\/?p=2784"},"modified":"2025-07-15T18:45:31","modified_gmt":"2025-07-15T09:45:31","slug":"fda-approves-gradual-alzheimers-drug-dosing","status":"publish","type":"post","link":"https:\/\/allaboutenglishmastery.com\/ko\/fda-approves-gradual-alzheimers-drug-dosing\/","title":{"rendered":"US FDA Approves Gradual Dosing for Lilly Alzheimer’s Drug"},"content":{"rendered":"

US FDA Approves Gradual Dosing for Lilly Alzheimer’s Drug<\/h1>\n\n\n\n

Advanced | July 16, 2025<\/h4>\n\n\n\n

\u2728<\/strong> \ud63c\uc790\uc11c \uae30\uc0ac\ub97c \uc18c\ub9ac \ub0b4\uc5b4 \uc77d\uac70\ub098 \ud29c\ud130\ub97c \ub530\ub77c \uac01 \ub2e8\ub77d\uc744 \ubc18\ubcf5\ud574\uc11c \uc77d\uc73c\uc138\uc694. \ub808\ubca8...<\/em><\/p>\n\n\n\n

\n\n\n\n

A Safer Approach to Alzheimer’s Treatment<\/h2>\n\n\n\n

Why the FDA Approves Gradual Alzheimer\u2019s Drug Dosing<\/h3>\n\n\n\n

In a significant development for Alzheimer’s patients, the U.S. Food and Drug Administration (FDA) has approved a modified, gradual dosing schedule for Eli Lilly’s Alzheimer’s disease drug, Kisunla (donanemab-azbt). This FDA-approved approach to gradual Alzheimer’s drug dosing aims to considerably lower the risk of a serious side effect: amyloid-related imaging abnormalities with edema\/effusion (ARIA-E), a form of brain swelling.<\/p>\n\n\n\n

Making Treatment Safer Without Sacrificing Results<\/h3>\n\n\n\n

This change is designed to make the treatment safer without reducing its effectiveness in clearing amyloid plaques, a hallmark of Alzheimer’s. This approval, granted on July 9, 2025, highlights the FDA\u2019s ongoing efforts to support safer long-term use of Alzheimer\u2019s medications through more gradual and personalized treatment approaches.<\/p>\n\n\n\n

Background on Kisunla and Initial Concerns<\/h3>\n\n\n\n

Kisunla, which received its initial FDA approval in July 2024, was the third drug to be cleared for slowing the progression of Alzheimer’s by targeting these harmful amyloid beta plaques. The original dosing regimen began with a higher dose of 700 mg intravenously for the first three months, followed by 1400 mg monthly thereafter. However, ARIA-E, while often asymptomatic, has been a significant concern, contributing to reluctance among physicians to prescribe the drug and even preventing its use in certain countries.<\/p>\n\n\n\n

The Science Behind the Shift<\/h3>\n\n\n\n

Results from Clinical Trials<\/h3>\n\n\n\n

To address these safety concerns, the new protocol introduces a more gradual increase in dosage. Patients will now receive a single 350 mg vial for their first monthly infusion, followed by two vials for the second month, three for the third, and then the full four vials (1400 mg) from the fourth month onward. Crucially, this ensures that patients still receive the same total dose by week 24, maintaining the drug’s therapeutic effect. This adjustment reflects the FDA\u2019s focus on minimizing health risks through gradual Alzheimer\u2019s drug dosing.<\/p>\n\n\n\n

This modified schedule is based on compelling data from the Phase 3b clinical trial, TRAILBLAZER-ALZ 6. The study demonstrated a remarkable 41% reduction in the incidence of ARIA-E at 24 weeks, decreasing from 24% with the original regimen to just 14% with the gradual dosing. Even at 52 weeks, the reduction remained significant at 35% (16% versus 25%). Importantly, the trial confirmed that this phased approach did not diminish Kisunla’s effectiveness, with patients still achieving an average of 67% reduction in amyloid plaques from baseline.<\/p>\n\n\n\n

Market Impact and Ongoing Research<\/h3>\n\n\n\n

Despite Kisunla’s proven potency in clearing plaques, its sales had been modest, reaching only \\$21 million in the first quarter of 2025. Safety concerns and the complexities of diagnosing and administering the treatment contributed to the slow sales. Eli Lilly expects the updated dosing schedule to significantly enhance the drug’s safety profile, which should help healthcare professionals feel more confident in evaluating and prescribing Kisunla as an appropriate treatment option for their patients. While Kisunla, which competes with drugs like Eisai and Biogen’s Leqembi, still carries a boxed safety warning for ARIA-E and ARIA-H (brain bleeding), Eli Lilly continues to research donanemab in ongoing clinical trials, including TRAILBLAZER-ALZ 3 and TRAILBLAZER-ALZ 5, to investigate its potential in slowing disease progression further.<\/p>\n\n\n\n

This case highlights why FDA approval of gradual Alzheimer\u2019s drug dosing can make a meaningful difference in public perception and adoption of new treatments.<\/p>\n\n\n\n

\n\n\n\n

Vocabulary<\/h2>\n\n\n\n
    \n
  1. Dosing schedule<\/strong> (noun): The plan or timetable for administering doses of a drug.\n